Company: CI
Filing Date: 2025-09-04
Form Type: 424B5
Source: 0001140361-25-033868
Chunk: 53

Company: Cigna Group
Filing Date: 2025-09-04
Form: 424B5
Chunk 53
---
 under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus until the offering of the particular securities covered by a prospectus supplement has been terminated or completed, other than any portion of the respective filings that are furnished, rather than filed, under the applicable SEC rules. This additional information is a part of this prospectus from the date of filing of those documents. To obtain a copy of these filings at no cost, you may write or telephone us at the following address: The Cigna Group Two Liberty Place, 1601 Chestnut Street Philadelphia, Pennsylvania 19192-1550 Attention: Shareholder Services Telephone: (215) 761-3516 E-mail: shareholderservices@evernorth.com Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference into such document.

iv

#### TABLE OF CONTENTS

### THE CIGNA GROUP
The Cigna Group, together with its subsidiaries, is a global health company committed to creating a better future for every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve.

Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. One of our business segments also offers health and dental insurance products to individuals in the United States and select international markets.

The Cigna Group’s principal executive offices are located at 900 Cottage Grove Road, Bloomfield, CT 06002. Our telephone number is (860) 226-6000.

For additional information concerning The Cigna Group, please see our most recent Annual Report on Form 10-K and our other filings with the SEC. See “Where You Can Find More Information.”

<div align='center'>1</div>

#### TABLE OF CONTENTS

### USE OF PROCEEDS
Unless we inform you otherwise in a prospectus supplement or free writing prospectus, the net proceeds from the sale of the securities will be added to The Cigna Group’s general funds and used for general corporate purposes, including the repayment of indebtedness.

We will not receive any proceeds from sales of securities offered by any selling security holders under this prospectus and the applicable